信迪利单抗转化治疗微卫星不稳定型III期结肠癌1例个案报道及文献复习
Conversion Therapy with Sintilimab for dMMR/MSI-H Stage III Colon Cancer: A Case Report and Literature Review
摘要: 既往研究表明，错配修复基因缺陷或微卫星不稳定型(dMMR/MSI-H)的晚期结直肠癌对传统化疗的反应较差。细胞程序性死亡受体(programmed death receptor 1, PD-1)/程序性死亡配体(programmed death ligand 1, PD-L1)信号通路阻断剂已成为这类肿瘤的有效治疗方法。我们报道一例III期dMMR/MSI-H结肠癌患者，接受了化疗联合信迪利单抗的转化治疗后顺利完成手术，并获得了MPR (病理性主要缓解，残余存活肿瘤 ≤ 10%)。
Abstract: Previous studies have shown that advanced colorectal cancer with mismatch repair gene defect or microsatellite instability (dMMR/MSI-H) has poor response to traditional chemotherapy. Pro-grammed death receptor (PD-1)/Programmed death ligand 1 (PD-L1) signal pathway blocker has become an effective therapy for this type of tumor. We report a patient with stage III dMMR/MSI-H colon cancer who successfully completed the operation after receiving chemotherapy combined with sintilimab conversion therapy and obtained MPR (pathological major response, residual sur-vival tumor ≤ 10%).
文章引用：闫敏, 于丽, 何信佳, 赵园园. 信迪利单抗转化治疗微卫星不稳定型III期结肠癌1例个案报道及文献复习[J]. 临床医学进展, 2023, 13(2): 2142-2147. https://doi.org/10.12677/ACM.2023.132300

参考文献

[1] Ferlay, J., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386. [Google Scholar] [CrossRef] [PubMed]
[2] Marino, D., et al. (2014) Potentially Resectable Metastatic Colorectal Cancer: An Individualized Approach to Conversion Therapy. Critical Reviews in Oncology/Hematology, 92, 218-226. [Google Scholar] [CrossRef] [PubMed]
[3] Benatti, P., et al. (2005) Microsatellite Instability and Colo-rectal Cancer Prognosis. Clinical Cancer Research, 11, 8332- 8340. [Google Scholar] [CrossRef] 
[4] Hoy, S. (2019) Sintilimab: First Global Approval. Drugs, 79, 341-346. [Google Scholar] [CrossRef] [PubMed]
[5] Lichtenstern, C.R., Ngu, R.K. and Shalapour, S. (2020) Immunotherapy, Inflammation and Colorectal Cancer. Cells, 9, 618. [Google Scholar] [CrossRef] [PubMed]
[6] Ganesh, K., et al. (2019) Immunotherapy in Colorectal Cancer: Rationale, Challenges and Potential. Nature Reviews Gastroenterology & Hepatology, 16, 361-375. [Google Scholar] [CrossRef] [PubMed]
[7] Chalabi, M., et al. (2020) Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers. Nature Medicine, 26, 566-576. [Google Scholar] [CrossRef] [PubMed]
[8] Benson, A.B., et al. (2021) Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19, 329-359.
[9] Zhang, L., et al. (2020) Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Frontiers in Oncology, 10, Article ID: 594558. [Google Scholar] [CrossRef] [PubMed]
[10] Liu,D.X., et al. (2020) PD-1 Blockade in Neo-adjuvant Setting of DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer. Oncoimmunology, 9, Article ID: 1711650.
[11] Wu, J. and Waxman, D.J. (2018) Immunogenic Chemotherapy: Dose and Schedule De-pendence and Combination with Immunotherapy. Cancer Letters, 419, 210-221. [Google Scholar] [CrossRef] [PubMed]
[12] Melichar, B., Touskova, M. and Vesely, P. (2002) Effect of Iri-notecan on the Phenotype of Peripheral Blood Leukocyte Populations in Patients with Metastatic Colorectal Cancer. Hep-atogastroenterology, 49, 967-970.
[13] Pere, H., et al. (2012) Comprehensive Analysis of Current Approaches to Inhib-it Regulatory T Cells in Cancer. Oncoimmunology, 1, 326-333. [Google Scholar] [CrossRef] [PubMed]
[14] Zhao, Y., et al. (2022) VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-Small Cell Lung Cancer: Targeting the Tumor Microenvironment. International Journal of Biological Sciences, 18, 3845-3858. [Google Scholar] [CrossRef] [PubMed]
[15] Terme, M., et al. (2013) VEGFA-VEGFR Pathway Blockade Inhibits Tu-mor-Induced Regulatory T-Cell Proliferation in Colorectal Cancer. Cancer Research, 73, 539-549. [Google Scholar] [CrossRef] 
[16] Tetzlaff, M.T., et al. (2018) Pathological Assessment of Resection Specimens after Neoadjuvant Therapy for Metastatic Melanoma. Annals of Oncology, 29, 1861-1868. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, Q., Gao, J. and Wu, X. (2018) Pseudoprogression and Hy-perprogression after Checkpoint Blockade. International Immunopharmacology, 58, 125-135. [Google Scholar] [CrossRef] [PubMed]
[18] Colle, R., et al. (2021) Pseudoprogression in Patients Treated with Immune Checkpoint Inhibitors for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. European Journal of Cancer, 144, 9-16. [Google Scholar] [CrossRef] [PubMed]

为你推荐